Results 131 to 140 of about 463,492 (156)

The choroid as a vascular sensor in pulmonary hypertension: an oculomic mini review. [PDF]

Front Cardiovasc Med
Dmuchowska DA.
europepmc   +1 more source

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis. [PDF]

Rheumatology (Oxford)
Kaufman J, Nabozny G, Tran-Manh C, Liebel C, Zhou X, Daley LA, Wang CT, Ebenezer DL, Delic D, Wohnhaas CT, Trinh-Minh T, Distler JHW.   +11 more
europepmc   +1 more source

Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study. [PDF]

J Diabetes Investig
Hiura K, Masuda H, Sakunami M, Yamashita M.   +3 more
europepmc   +1 more source

Pulmonary Arterial Hypertension: Recognition and Management in Primary and Acute Care Settings. [PDF]

Cureus
Ahern BJ, Fulford ST, Long D, Miller CL.
europepmc   +1 more source

Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies. [PDF]

Intractable Rare Dis Res
Chu KY.
europepmc   +1 more source

Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. [PDF]

Eur Respir J
Dong F, Lin H, Han Y.
europepmc   +1 more source

Heart failure in 2025: new insights, therapies, and clinical directions. [PDF]

J Thorac Dis
Shen Z, Zheng P, Gu G, Zhang Y, Chen Z, Qian J.   +5 more
europepmc   +1 more source

Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016-2026). [PDF]

Cardiovasc Diabetol
Wen S, Wang C, Xu Z, Chen L, He Y, Ren Y, Yuan Y, Li Y, Dong M, Gong M, Wang C, Li X, Xu D, Yuan X, Jin J, Li J, Zhou L.   +16 more
europepmc   +1 more source

Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum [PDF]

European Journal of Heart Failure, 2022
Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state.
Christopher M O'Connor, Robert O Blaustein   +1 more
exaly   +3 more sources